Prognostic value of systemic immune-inflammation index in patients with gastric cancer treated with immune checkpoint inhibitors

doi:10.3748/wjg.v32.i34.119567

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 34

This Article

(5)

(4)

(0)

(13)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Sep 14, 2026; 32(34): 119567
Published online Sep 14, 2026. doi: 10.3748/wjg.v32.i34.119567

Table 5 Comparison of baseline information of gastric cancer patients in the high and low systemic immune-inflammation index groups, n (%)/mean ± SD

Parameters	Low SII group (n = 128)	High SII group (n = 110)	t/χ²	P value
Gender			0.054	0.816
Female	47 (36.72)	42 (38.18)
Male	81 (63.28)	68 (61.82)
Age (years)	62.45 ± 3.97	63.02 ± 4.05	1.101	0.272
Body mass index (kg/m²)	22.18 ± 3.01	21.87 ± 3.08	0.790	0.430
Eastern Cooperative Oncology Group			8.111	0.017
0	67 (52.34)	43 (39.09)
1	48 (37.50)	42 (38.18)
2	13 (10.16)	25 (22.73)
Clinical staging			7.363	0.007
IV	82 (64.06)	88 (80.00)
III	46 (35.94)	22 (20.00)
Number of distant metastases			6.151	0.013
≥ 2	55 (42.97)	65 (59.09)
< 2	73 (57.03)	45 (40.91)
Previous gastric cancer resection surgery			1.460	0.227
Yes	60 (46.88)	43 (39.09)
No	68 (53.12)	67 (60.91)
Treatment regimen			0.014	0.904
Combination therapy	65 (50.78)	55 (50.00)
Monotherapy	63 (49.22)	55 (50.00)
Programmed cell death ligand 1 overexpression (combined positive score)			0.045	0.831
≥ 1	82 (64.06)	69 (62.73)
< 1	46 (35.94)	41 (37.27)

SII: Systemic immune-inflammation index.

Full Size Table

Citation: Guo R, Gao M. Prognostic value of systemic immune-inflammation index in patients with gastric cancer treated with immune checkpoint inhibitors. World J Gastroenterol 2026; 32(34): 119567
URL: https://www.wjgnet.com/1007-9327/full/v32/i34/119567.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i34.119567

Guo R, Gao M. Prognostic value of systemic immune-inflammation index in patients with gastric cancer treated with immune checkpoint inhibitors. World J Gastroenterol 2026; 32(34): 119567 [DOI: 10.3748/wjg.v32.i34.119567]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.